Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for (Study ST002672)

(Analysis AN004344)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12	F13	F14
histidine	ME632211	0.55	0.61	0.66	0.73	8.93	0.55	0.59	0.55	0.48	0.56	0.58	0.53	0.59	0.62
phenyllactate	ME632215	0.26	1.08	1.36	1.25	0.54	0.17	0.25	4.31	0.41	1.38	0.15	0.55	0.31	1.73
FA(10:0-OH)	ME632225	0.63	0.55	1.77	1.79	3.98	0.77	0.66	0.48	0.56	0.55	0.50	0.45	0.71	0.49
hydroxyphenyllactic acid	ME632222	0.86	0.69	0.79	0.90	5.08	0.73	0.99	0.57	0.88	0.60	0.90	0.61	0.98	0.70
taurohyodeoxycholate	ME632291	1.14	0.49	1.08	0.97	0.36	0.26	3.38	1.07	2.07	0.79	1.06	0.75	0.51	0.36
tauroursodeoxycholate	ME632290	1.14	0.51	1.07	0.97	0.35	0.26	3.37	1.06	2.07	0.78	1.05	0.77	0.51	0.37
beta-muricholate	ME632280	1.33	0.11	0.91	0.79	0.54	1.24	4.09	0.09	2.27	1.05	1.07	0.02	0.44	0.16
cholate	ME632281	1.33	0.11	0.91	0.79	0.52	1.24	4.10	0.09	2.27	1.05	1.07	0.02	0.44	0.16
glycohyodeoxycholate	ME632284	0.69	0.39	1.07	0.86	0.45	0.22	4.84	0.56	2.71	0.59	0.63	0.39	0.67	0.40
glycoursodeoxycholate	ME632283	0.70	0.40	1.07	0.87	0.44	0.22	4.78	0.56	2.71	0.59	0.63	0.39	0.67	0.41
taurochenodeoxycholate	ME632292	0.54	0.26	1.13	1.09	0.65	0.09	4.21	1.65	3.67	0.84	0.41	0.89	0.22	0.15
ursodeoxycholate	ME632277	0.61	0.22	0.94	1.02	2.09	0.26	3.49	0.71	3.30	0.61	0.37	0.50	0.38	0.20
lithocholate glycine conjugate	ME632282	1.22	NA	1.02	0.76	NA	0.76	1.06	NA	1.45	NA	1.17	0.59	1.02	0.87
taurocholate	ME632297	1.94	1.66	1.13	1.18	0.03	0.15	2.24	0.92	1.69	0.90	2.02	0.62	0.50	0.57
xanthosine	ME632254	0.55	0.40	0.94	1.37	0.18	0.72	1.92	0.53	1.28	0.84	1.54	0.45	1.75	1.17
glycocholate	ME632287	1.79	1.24	1.08	1.16	0.06	0.27	2.64	0.28	1.34	0.64	1.80	0.13	1.59	0.75
glycohyocholate	ME632288	1.76	1.04	1.14	1.09	0.05	0.26	2.71	0.27	1.44	0.62	2.06	0.11	1.54	0.73
glycochenodeoxycholate	ME632285	1.71	0.60	0.96	1.06	0.56	0.53	2.47	0.35	1.39	0.48	1.59	0.28	1.54	0.67
urate	ME632216	1.32	0.52	1.01	1.01	0.41	0.73	1.94	0.47	1.50	0.78	1.51	0.49	1.49	0.84
S-allylcysteine	ME632213	1.55	1.97	1.41	1.38	0.06	0.87	0.56	0.48	0.20	0.24	0.53	0.94	2.04	1.49
3-hydroxybutyrate	ME632194	1.36	0.52	1.02	0.93	2.07	0.65	1.59	0.51	1.64	0.65	1.05	0.60	1.36	0.53
glutarate	ME632202	1.04	1.15	1.04	0.93	1.64	0.70	1.97	0.76	0.78	0.90	0.60	0.96	1.11	0.79
kynurenate	ME632226	1.03	0.89	0.78	0.89	1.55	0.68	2.53	0.71	0.79	0.99	0.58	0.69	1.58	0.95
FA(11:0-COOH)	ME632235	0.50	0.63	1.84	1.86	2.62	0.83	0.74	0.63	0.59	0.54	0.61	0.56	0.70	0.57
FA(10:0-COOH)	ME632231	0.77	0.78	1.35	1.68	2.61	0.84	0.97	0.71	0.85	0.70	0.71	0.66	0.86	0.70
N-methylaspartate	ME632208	0.79	0.88	1.27	1.35	2.23	0.94	0.83	0.83	0.72	0.80	0.75	0.72	0.75	0.87
succinate	ME632197	1.05	1.01	0.89	0.91	2.88	1.01	1.09	0.68	0.86	0.80	0.89	0.78	0.99	0.74
ketoleucine	ME632201	1.07	0.82	0.93	0.87	2.52	1.07	0.89	0.84	1.10	0.79	0.87	0.82	1.04	0.86
3-methyl-2-oxovalerate	ME632200	0.99	0.86	0.96	0.92	2.00	1.23	0.89	0.83	1.12	0.83	0.83	0.85	1.03	0.87
indole lactate	ME632233	0.86	0.86	0.94	1.06	2.26	1.08	0.96	0.81	0.99	0.77	0.83	0.93	0.97	0.88
FA(15:0)	ME632241	1.04	0.82	1.07	1.14	1.88	1.22	0.80	0.77	1.32	0.93	0.87	0.99	1.13	1.01
FA(17:0)	ME632248	0.81	1.13	1.24	1.13	1.86	1.33	0.80	0.89	0.97	1.05	0.76	1.08	1.11	0.95
chenodeoxycholate	ME632274	0.82	0.59	1.24	2.56	1.77	0.51	1.38	0.53	1.32	0.74	0.59	0.46	0.52	0.51
FA(12:0)	ME632230	0.63	0.93	1.80	1.93	1.73	0.96	0.65	0.59	0.52	0.61	0.70	0.64	0.83	0.80
FA(8:0-COOH)	ME632219	0.65	0.71	1.82	1.87	0.85	0.82	0.67	0.71	0.69	0.70	0.70	0.70	0.67	0.69
FA(9:0-COOH)	ME632224	0.73	0.65	1.87	1.99	1.32	0.94	0.91	0.58	0.93	0.49	0.74	0.53	0.75	0.60
glycodeoxycholate	ME632286	0.71	1.61	1.18	1.13	0.18	0.66	1.65	0.84	0.62	1.06	0.78	0.50	0.77	2.01
taurohyocoholate	ME632293	1.58	2.06	1.21	1.33	0.09	0.14	1.62	1.42	0.88	1.06	1.26	1.03	0.27	1.33
tauro-alpha-muricholate	ME632294	0.95	2.16	1.12	1.10	0.07	0.31	1.52	1.16	0.92	1.59	1.05	0.61	0.38	1.03
tauro-alpha-muricholate + tauro-beta-muricholiate	ME632295	0.98	2.14	1.11	1.10	0.07	0.34	1.51	1.14	0.96	1.59	1.03	0.61	0.38	1.01
tauro-beta-muricholate	ME632296	0.98	2.14	1.12	1.11	0.07	0.33	1.51	1.14	0.96	1.59	1.03	0.61	0.38	1.01
retinoate	ME632258	0.99	0.96	1.10	1.00	0.84	0.50	1.02	1.00	1.09	1.04	0.93	1.07	2.70	0.98
FA(16:0-COOH)	ME632256	1.39	0.92	1.16	1.05	0.16	1.41	1.48	0.64	1.30	0.72	0.78	0.65	1.07	0.66
alpha-muricholate	ME632278	1.31	1.07	1.06	0.94	0.28	1.28	1.87	0.46	0.74	1.19	1.21	0.47	0.93	0.88
omega-muricholate	ME632279	1.30	1.07	1.07	0.94	0.29	1.28	1.88	0.46	0.74	1.19	1.20	0.47	0.94	0.87
deoxycholate	ME632275	0.95	0.82	1.17	1.12	1.16	1.07	1.94	0.68	1.39	0.70	0.76	0.71	0.64	0.58
hydroxyindole acetate	ME632227	1.33	1.57	1.02	1.05	0.32	1.38	1.53	1.02	1.11	0.79	0.83	0.76	0.45	0.37
hyodeoxycholate	ME632276	0.82	1.22	0.91	1.02	0.50	1.06	1.84	1.14	1.20	0.83	0.70	1.10	0.76	0.83
threonine	ME632198	0.65	0.66	0.80	1.92	0.39	0.75	0.82	1.34	0.71	0.95	0.80	0.94	0.95	0.85
2-hydroxybutyrate	ME632193	1.00	1.02	1.12	1.38	1.63	1.32	0.81	0.63	0.98	0.71	0.62	0.74	0.83	0.59
uridine	ME632242	0.79	1.12	1.22	1.47	1.20	1.24	0.85	0.62	0.76	0.74	0.70	0.69	1.07	0.63
FA(22:0)	ME632269	0.84	1.26	1.34	1.43	1.12	0.73	0.92	1.10	0.87	1.18	0.80	0.89	1.25	1.04
FA(24:0)	ME632272	0.90	1.26	1.28	1.42	0.90	0.76	0.97	1.18	0.94	1.15	0.81	0.87	1.20	1.21
FA(12:0-OH)	ME632236	0.87	1.16	1.10	1.18	1.43	1.24	0.69	0.96	0.66	0.97	0.62	0.78	0.83	1.15
FA(20:0)	ME632264	0.77	1.34	1.32	1.27	1.51	1.02	0.87	1.08	0.86	1.15	0.76	0.90	1.10	1.03
FA(16:0)	ME632245	0.83	1.27	1.19	1.31	1.37	1.35	0.79	0.84	0.72	1.13	0.86	1.11	1.20	0.84
FA(18:0)	ME632255	0.92	1.12	1.24	1.35	1.42	1.14	0.82	0.92	0.94	1.01	0.87	0.99	1.20	0.82
N-acetylleucine	ME632217	1.12	0.86	1.04	1.29	0.54	0.77	1.44	0.77	1.19	0.86	1.07	0.68	1.04	0.97
lactate	ME632192	1.11	0.97	1.08	1.07	1.50	1.21	1.37	0.85	1.22	0.97	1.19	0.77	1.19	0.92
FA(14:2)	ME632237	1.00	1.16	1.15	1.16	1.17	0.79	0.87	0.89	0.92	0.92	0.79	0.81	1.00	1.18
malate	ME632204	1.07	0.93	0.88	1.11	1.42	1.04	1.19	0.83	1.04	0.88	0.94	0.79	1.04	0.89
gamma-glutamylisoleucine	ME632246	1.02	1.01	1.12	1.13	1.20	0.85	1.00	0.90	0.99	0.94	0.94	0.76	1.13	0.87
serine	ME632195	1.07	1.02	1.07	1.19	1.41	0.92	1.00	0.98	0.95	0.95	0.99	0.97	1.22	0.86
N-acetylphenylalanine	ME632234	1.10	0.99	1.00	1.24	0.73	1.08	1.15	0.94	1.24	0.65	0.92	0.93	0.83	0.79
tryosine	ME632221	1.01	1.00	0.89	0.95	0.72	0.80	1.14	1.00	1.13	1.05	1.16	1.06	1.16	1.15
taurine	ME632199	1.16	1.07	1.00	1.03	1.13	1.27	1.22	1.00	1.13	0.94	1.17	0.97	1.12	1.03
phenylalanine	ME632214	1.02	1.04	1.04	1.07	0.88	0.90	1.06	0.90	1.03	0.93	1.04	0.94	1.08	0.99
indoleacrylate	ME632223	0.99	1.00	0.98	1.00	0.91	1.12	1.05	0.88	1.12	0.88	1.04	0.93	1.07	0.97
tryptophan	ME632232	1.04	0.99	0.99	0.97	0.89	1.14	1.09	0.87	1.11	0.87	1.03	0.91	1.09	0.96
hippurate	ME632220	1.29	1.00	0.99	0.95	0.78	1.39	0.90	0.39	0.97	0.80	1.06	0.82	1.65	0.80
deoxycytidine	ME632239	0.84	1.24	1.05	0.98	0.46	0.95	0.90	1.35	0.92	1.33	0.81	1.23	0.91	0.91
sphingosine-1P (C18)	ME632273	0.91	0.84	1.09	1.02	0.65	0.99	1.24	1.49	1.07	1.65	1.34	1.07	1.07	0.94
FA(8:0-OH)	ME632212	0.79	1.09	1.46	1.32	0.41	1.30	0.72	0.95	0.66	1.06	0.57	0.69	0.82	1.00
taurodeoxycholate	ME632289	1.00	0.89	1.26	1.40	0.08	0.82	0.73	0.75	0.63	0.92	1.10	1.20	1.55	0.85
FA(16:0-OH)	ME632249	1.01	1.36	1.22	1.63	0.28	0.80	0.98	0.90	0.93	1.04	0.83	1.10	1.26	1.11
FA(24:1)	ME632271	0.90	1.24	1.24	1.27	0.03	0.79	0.92	1.06	1.00	1.07	0.75	0.92	1.23	0.95
maleate	ME632196	1.10	1.17	0.83	0.54	0.43	1.31	1.27	1.07	1.16	1.17	1.12	1.04	1.11	1.10
3,4-dihydroxybenzoate	ME632210	1.14	1.13	0.84	0.86	0.34	1.39	0.89	1.04	0.94	1.09	1.11	0.92	1.37	0.91
cis-aconitate	ME632218	1.25	0.86	0.98	0.94	0.43	1.40	0.96	0.83	0.99	0.89	0.89	1.09	1.50	0.71
FA(14:0-OH)	ME632243	1.42	1.37	0.98	1.13	0.21	1.16	1.18	1.13	1.16	1.01	1.00	0.89	1.33	0.90
FA(12:1)	ME632229	1.14	1.03	1.15	1.21	0.31	0.96	1.06	0.89	1.25	0.93	1.04	0.91	1.20	1.05
citrate	ME632228	1.08	1.03	1.04	1.06	0.41	1.11	1.13	0.91	1.13	0.95	1.05	0.91	1.07	0.83
aspartate	ME632203	1.21	1.10	0.94	1.08	0.17	1.05	1.20	0.98	1.09	0.92	1.06	0.93	1.11	0.92
gamma-glutamylleucine	ME632247	1.09	1.14	1.05	1.03	0.22	1.10	1.05	1.04	1.05	0.99	1.04	0.93	1.07	0.92
glutamate	ME632209	1.20	0.92	0.89	0.95	0.16	1.12	1.15	1.15	1.09	1.02	1.05	1.22	0.97	1.04
glutamine	ME632207	1.10	1.10	1.02	1.01	0.46	1.18	1.17	1.18	1.11	1.11	1.05	1.03	1.00	1.04
FA(18:4)	ME632250	1.22	1.17	1.06	1.13	0.60	1.19	0.79	0.69	0.71	0.66	0.95	1.35	1.30	0.79
m-hydroxybenzoate	ME632206	0.99	1.03	1.17	1.26	0.79	1.07	0.62	0.83	0.71	0.76	0.81	1.16	1.13	1.09
AMP	ME632270	0.93	1.33	1.17	1.12	0.04	1.26	0.87	0.88	0.92	0.93	0.94	1.14	0.87	0.95
FA(18:1)	ME632253	0.90	1.43	1.18	1.23	0.68	1.51	0.84	0.77	0.75	1.13	0.83	1.07	1.29	1.16
FA(18:2)	ME632252	0.93	1.33	1.11	1.06	0.70	1.69	0.86	0.86	0.79	1.12	0.93	1.25	1.18	1.08
FA(16:1)	ME632244	1.25	1.50	0.95	1.15	0.27	1.32	0.88	0.84	0.98	1.03	1.06	1.24	1.54	1.10
FA(14:0)	ME632240	1.13	1.27	1.34	1.23	0.22	1.44	0.79	0.83	0.87	0.94	0.99	1.10	1.34	0.92
FA(18:3)	ME632251	1.13	1.41	1.15	1.24	0.24	1.63	0.77	0.76	0.78	0.90	0.99	1.35	1.33	0.93
FA(19:1)	ME632257	0.83	1.22	1.11	1.33	0.35	1.12	0.66	0.70	0.96	0.90	0.77	1.07	1.31	0.98
FA(14:1)	ME632238	1.08	1.21	1.07	1.17	0.56	1.07	0.96	0.89	1.16	0.97	0.83	0.89	1.24	1.24
FA(22:6(4Z,7Z,10Z,16Z,19Z))	ME632265	1.18	1.56	1.14	1.23	0.52	1.10	1.05	0.83	0.82	1.05	0.86	1.04	1.32	1.30
FA(20:1)	ME632263	0.87	1.37	1.23	1.23	0.27	1.39	1.01	0.98	0.97	1.14	0.81	1.19	1.19	1.07
FA(20:4)	ME632260	0.99	1.52	1.10	1.31	0.34	1.23	0.95	0.89	0.87	1.12	0.89	1.16	1.29	1.17
FA(22:5)	ME632266	0.96	1.85	1.34	1.36	0.02	0.70	0.85	0.71	0.79	1.40	0.70	0.89	1.76	1.48
FA(22:3)	ME632268	0.86	1.67	1.15	1.24	0.14	0.90	0.77	0.70	0.65	0.95	0.69	0.84	1.34	1.55
FA(22:4)	ME632267	0.99	1.70	1.27	1.08	0.11	1.13	0.95	0.94	0.77	1.25	0.80	1.10	1.35	1.55
FA(20:2)	ME632262	0.71	1.36	1.01	1.41	0.05	1.34	0.83	1.11	0.70	1.26	0.81	1.34	1.43	1.34
FA(20:3)	ME632261	0.82	1.50	1.05	1.41	0.04	1.05	0.84	0.86	0.58	1.23	0.73	1.14	2.02	1.57
FA(20:5(5Z,8Z,11Z,14Z,17Z)))	ME632259	0.77	1.42	1.11	1.46	0.15	1.01	0.86	0.81	0.39	0.70	1.06	2.00	1.65	1.35
phenylacetate	ME632205	0.75	1.61	1.30	1.06	0.46	0.82	0.49	0.88	0.44	0.97	1.03	1.51	1.00	1.30

Factors:

F1	Group:Control \| Timepoint:8 weeks of training or control time \| Sex:Female
F2	Group:Control \| Timepoint:8 weeks of training or control time \| Sex:Male
F3	Group:QC-DriftCorrection \| Timepoint:0 hour \| Sex:-
F4	Group:QC-Pooled \| Timepoint:0 hour \| Sex:-
F5	Group:QC-ReCAS \| Timepoint:0 hour \| Sex:-
F6	Group:QC-Reference \| Timepoint:0 hour \| Sex:-
F7	Group:Training \| Timepoint:1 week of training or control time \| Sex:Female
F8	Group:Training \| Timepoint:1 week of training or control time \| Sex:Male
F9	Group:Training \| Timepoint:2 weeks of training \| Sex:Female
F10	Group:Training \| Timepoint:2 weeks of training \| Sex:Male
F11	Group:Training \| Timepoint:4 weeks of training \| Sex:Female
F12	Group:Training \| Timepoint:4 weeks of training \| Sex:Male
F13	Group:Training \| Timepoint:8 weeks of training or control time \| Sex:Female
F14	Group:Training \| Timepoint:8 weeks of training or control time \| Sex:Male

Data matrix